-
AIPLA CLE Webinar: Post-Grant Strategies for Correcting and Challenging Patent Claims
March 4, 2020 12:30 PM to 2:00 PM | 1.5 CLE Credits
This webinar will provide a summary of post-grant procedures and describe when, why, and how each procedure is useful (or not) to patent owners and third-party challengers.
-
AIPLA CLE Webinar: Post-Grant Strategies for Correcting and Challenging Patent Claims
March 4, 2020 12:30 PM to 2:00 PM | 1.5 CLE Credits
This webinar will provide a summary of post-grant procedures and describe when, why, and how each procedure is useful (or not) to patent owners and third-party challengers.
-
AIPLA CLE Webinar: Post-Grant Strategies for Correcting and Challenging Patent Claims
March 4, 2020 12:30 PM to 2:00 PM | 1.5 CLE Credits
This webinar will provide a summary of post-grant procedures and describe when, why, and how each procedure is useful (or not) to patent owners and third-party challengers.
News
-
Daily Fantasy Sites Don’t Violate College Athlete Rights
November 5, 2018
The Indiana Supreme Court, on October 24, 2018, answered a certified question from the US Court of Appeals for the Seventh Circuit on whether online for-profit fantasy-sports need the consent of players whose names, pictures, and statistics are used in the contests, in advertising the contests, or both. -
Relevant Prior Art Initiative to Increase Examination Quality
November 2, 2018
The USPTO has announced that Phase 1 of its Access to Relevant Prior Art (RPA) Initiative will begin Nov. 1, 2018. -
PTAB Proposes Changes to Motion to Amend Practice in AIA Trials
November 1, 2018
The USPTO has published a Request for Comments (RFC) on a proposed procedure for motions to amend filed in AIA trials before the PTAB. -
Registration Open for Inventor STEPP Training
October 31, 2018
Registration is now open for the Feb. 5 - 7, 2019 USPTO Inventor 3-Day Course on Examination Practice and Procedure. -
CAFC Affirms Invalidation of Patents for MS Drug Copaxone
October 19, 2018
The Federal Circuit on October 12, 2018, affirmed a district court decision invalidating Teva’s patents for Copaxone, its best-selling multiple sclerosis drug.